Brain Benefits Boost Roche's Alecensa In ALK Lung Cancer Race

 
• By Kevin Grogan

Data from two studies confirm Alecensa's superiority over Pfizer's Xalkori and help Roche close the gap on Novartis' Zykadia.

street cars racing in blurred action
Roche looks to overtake the opposition in the ALK lung cancer market • Source: Shutterstock

More from Anticancer

More from Therapy Areas